- CAHtalyst Pediatric and CAHtalyst Adult Baseline Characteristics Data in Congenital Adrenal Hyperplasia
- Phase 2 (CHAMPAIN) Clinical Study Data for Modified-Release Hydrocortisone (Chronocort/Efmody) in Adrenal Insufficiency
- Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia
SAN DIEGO, May 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including baseline characteristics data from its CAHtalyst Program of crinecerfont in congenital adrenal hyperplasia (CAH), as well as data from its modified-release hydrocortisone studies in primary adrenal insufficiency and CAH, at the European Congress of Endocrinology 2024 meeting in Sweden, May 11–14.
Neurocrine Biosciences will be presenting several abstracts and posters at ECE 2024, including:
- Baseline Characteristics of Children and Adolescents with Classic Congenital Adrenal Hyperplasia Enrolled in CAHtalyst Pediatric, a Phase 3 Study of Crinecerfont, a Corticotropin-Releasing Factor Type 1 Receptor Antagonist
- May 13; 5:30–6:30pm (Poster# P225)
- Baseline Characteristics of Adults with Classic Congenital Adrenal Hyperplasia Enrolled in CAHtalyst Adult, a Phase 3 Study of Crinecerfont, a Corticotropin-Releasing Factor Type 1 Receptor Antagonist
- May 14; 1:40–3:10pm (Poster# P423)
- CHAMPAIN study: Initial Results from a Phase II Study of Efficacy, Safety and Tolerability of Modified-Release Hydrocortisones: Chronocort (Efmody) versus Plenadren, in Primary Adrenal Insufficiency,
- May 12; 2:00–2:40pm (Rapid Communication #RC3.4)
- Biochemical Control with Dose Reduction in Chronic Glucocorticoid Therapy over 4 Years: A Phase III Extension Study of Chronocort (Efmody) in the Treatment of Congenital Adrenal Hyperplasia (CAH)
- May 12; 2:00–2:40pm (Rapid Communication #RC3.1)
- Incidence of Adrenal Crisis in Congenital Adrena Hyperplasia (CAH) Patients During a Prospective Monitored Long-Term study of Modified-Release Hydrocortisone (MRHC) Capsules, (Efmody)
- May 12; 4:20–6:00pm (Poster #P215)
- Morning Cortisol Levels in Patients with Established Primary Adrenal Insufficiency
- May 13; 5:30– 6:30pm (Poster #P13)